BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Nov 15, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MLN4924: Preliminary Phase I data

Preliminary data from an ongoing, dose-escalation Phase I trial in 15 patients with AML or high-grade MDS showed that MLN4924 produced 3 complete responses. Two dose-limiting toxicities were reported at the 78 mg/m 2 MLN4924 dose - multi-organ failure...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >